Koji Sasaki
About
Koji Sasaki is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Koji Sasaki has authored 371 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 263 papers in Hematology, 163 papers in Genetics and 115 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Koji Sasaki's work include Chronic Myeloid Leukemia Treatments (142 papers), Acute Myeloid Leukemia Research (136 papers) and Acute Lymphoblastic Leukemia research (109 papers). Koji Sasaki is often cited by papers focused on Chronic Myeloid Leukemia Treatments (142 papers), Acute Myeloid Leukemia Research (136 papers) and Acute Lymphoblastic Leukemia research (109 papers). Koji Sasaki collaborates with scholars based in United States, Japan and France. Koji Sasaki's co-authors include Hagop M. Kantarjian, Elias Jabbour, Farhad Ravandi, Nicholas J. Short, Jörge E. Cortes, Guillermo Garcia‐Manero, Tapan M. Kadia, Gautam Borthakur, Naval Daver and Marina Konopleva and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Koji Sasaki
337 papers receiving 4.7k citations
Hit Papers
Peers
Koji Sasaki
Vincent H. J. van der Velden Netherlands
Tadakazu Kondo Japan
Francis Lacombe France
Bruce H. Davis United States
Lloyd B. Klickstein United States
Brian W. Grinnell United States
Michael Martin United States
Hugh M. Davis United States
Henri H. Versteeg Netherlands
Martin L. Olsson Sweden
Citations per year, relative to Koji Sasaki Koji Sasaki (= 1×)
peers
Vincent H. J. van der Velden
Countries citing papers authored by Koji Sasaki
Since
Specialization
Citations
This map shows the geographic impact of Koji Sasaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Sasaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Sasaki more than expected).
Fields of papers citing papers by Koji Sasaki
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Koji Sasaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Sasaki. The network helps show where Koji Sasaki may publish in the future.
Co-authorship network of co-authors of Koji Sasaki
This figure shows the co-authorship network connecting the top 25 collaborators of Koji Sasaki. A scholar is included among the top collaborators of Koji Sasaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Sasaki. Koji Sasaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kantarjian, Hagop M., Yifan Zhai, Vivian G. Oehler, et al.. (2025). Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research. Cancer. 131(8). e35832–e35832.
2.
Kantarjian, Hagop, Koji Sasaki, Nitin B. Jain, et al.. (2025). Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Blood. 146(Supplement 1). 1566–1566.
3.
Fukuda, Takeshi, Takeshi Kuribayashi, Koji Sasaki, et al.. (2024). Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia. Bioorganic & Medicinal Chemistry Letters. 108. 129799–129799.
4.
Mill, Christopher P., Warren Fiskus, Christine Birdwell, et al.. (2024). ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents. Blood. 144(Supplement 1). 1349–1349.
5.
Kantarjian, Hagop M., Fadi Haddad, Nicholas J. Short, et al.. (2024). Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6605–6605.
6.
Ozawa, Yoko, et al.. (2023). Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration. Scientific Reports. 13(1). 10597–10597.
7.
Sasaki, Koji, Fadi Haddad, Nicholas J. Short, et al.. (2023). Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019. Cancer. 129(23). 3805–3814.
8.
Matsuo, Takahiro, Sebastian Wurster, Ying Jiang, et al.. (2023). Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. Journal of Antimicrobial Chemotherapy. 79(2). 297–306.
9.
Borthakur, Gautam, Koji Sasaki, Guilin Tang, et al.. (2023). Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results. Blood. 142(Supplement 1). 2903–2903.
10.
Nahmod, Karen, Koji Sasaki, Chi Young Ok, & Sanam Loghavi. (2023). Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. American Journal of Hematology. 99(2). 329–330.
11.
Oshikawa, Gaku & Koji Sasaki. (2023). Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities. Cancers. 15(8). 2399–2399.
12.
Senapati, Jayastu, Sanam Loghavi, Nicholas J. Short, et al.. (2023). Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 142(19). 1647–1657.
13.
Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2023). The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR ::ABL1 tyrosine kinase inhibitors. American Journal of Hematology. 98(4). 658–665.
14.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2023). The role of therapy in the outcome of patients with myelofibrosis. Cancer. 129(18). 2828–2835.
15.
Ohji, Masahito, et al.. (2021). Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefe s Archive for Clinical and Experimental Ophthalmology. 259(12). 3637–3647.
16.
Sasaki, Koji, Elias Jabbour, Nicholas J. Short, et al.. (2021). Acute lymphoblastic leukemia: A population‐based study of outcome in the U nited S tates based on the surveillance, epidemiology, and end results (SEER ) database, 1980 –2017 . American Journal of Hematology. 96(6). 650–658.
17.
Monden, Yu, et al.. (2020). Management of Recurrent Pterygium with Severe Symblepharon Using Mitomycin C, Double Amniotic Membrane Transplantation, Cryopreserved Limbal Allograft, and a Conjunctival Flap. SHILAP Revista de lepidopterología.
18.
Jain, Preetesh, Hagop M. Kantarjian, Prajwal Boddu, et al.. (2019). Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advances. 3(6). 851–861.
19.
Jabbour, Elias, Koji Sasaki, Farhad Ravandi, et al.. (2019). Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 125(15). 2579–2586.
20.
Sasaki, Koji & Toshiyuki Murakami. (2007). Vibration Suppression Control of Redundant Manipulator with Flexible Structure by Considering Nullspace Motion. IEEJ Transactions on Industry Applications. 127(10). 1043–1049.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vincent H. J. van der Velden Breakdown of academic impact, for papers by Tadakazu Kondo Breakdown of academic impact, for papers by Francis Lacombe Breakdown of academic impact, for papers by Bruce H. Davis Breakdown of academic impact, for papers by Lloyd B. Klickstein Breakdown of academic impact, for papers by Brian W. Grinnell Breakdown of academic impact, for papers by Michael Martin Breakdown of academic impact, for papers by Hugh M. Davis Breakdown of academic impact, for papers by Henri H. Versteeg Breakdown of academic impact, for papers by Martin L. Olsson